Clinical Trial Update: Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 comparative study of BAT2206 versus Stelara® in moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• BAT2206
• Stelara (ustekinumab)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED